Advaxis Inc. (ADXS) Research Coverage Started at Cantor Fitzgerald
Cantor Fitzgerald assumed coverage on shares of Advaxis Inc. (NASDAQ:ADXS) in a report issued on Tuesday. The firm set a “buy” rating and a $19.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 121.96% from the company’s current price.
A number of other brokerages have also commented on ADXS. Jefferies Group reiterated a “buy” rating on shares of Advaxis in a research report on Thursday, August 4th. HC Wainwright reissued a “buy” rating and issued a $23.00 price target on shares of Advaxis in a research note on Friday, August 5th. Finally, Barclays PLC increased their price target on Advaxis from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, August 3rd. Six research analysts have rated the stock with a buy rating, Advaxis has a consensus rating of “Buy” and an average target price of $23.67.
Shares of Advaxis (NASDAQ:ADXS) traded down 3.82% on Tuesday, hitting $8.56. The stock had a trading volume of 825,315 shares. Advaxis has a 1-year low of $5.21 and a 1-year high of $16.30. The firm’s 50-day moving average is $9.24 and its 200 day moving average is $9.85. The stock’s market cap is $341.06 million.
ILLEGAL ACTIVITY WARNING: “Advaxis Inc. (ADXS) Research Coverage Started at Cantor Fitzgerald” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/29/advaxis-inc-adxs-research-coverage-started-at-cantor-fitzgerald.html.
In related news, insider Gregory T. Mayes sold 19,162 shares of the firm’s stock in a transaction on Tuesday, October 25th. The stock was sold at an average price of $8.23, for a total transaction of $157,703.26. Following the sale, the insider now owns 103,087 shares of the company’s stock, valued at approximately $848,406.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel O’connor sold 8,240 shares of the firm’s stock in a transaction on Wednesday, November 2nd. The stock was sold at an average price of $8.32, for a total value of $68,556.80. Following the sale, the chief executive officer now directly owns 303,127 shares in the company, valued at approximately $2,522,016.64. The disclosure for this sale can be found here. Corporate insiders own 4.56% of the company’s stock.
A number of hedge funds have recently modified their holdings of the company. BlackRock Advisors LLC increased its stake in shares of Advaxis by 10.6% in the second quarter. BlackRock Advisors LLC now owns 14,463 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 1,389 shares during the last quarter. Koshinski Asset Management Inc. acquired a new stake in shares of Advaxis during the third quarter valued at approximately $156,000. State Board of Administration of Florida Retirement System increased its stake in shares of Advaxis by 10.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 20,295 shares of the biotechnology company’s stock valued at $164,000 after buying an additional 1,940 shares during the last quarter. Nationwide Fund Advisors increased its stake in shares of Advaxis by 5.5% in the second quarter. Nationwide Fund Advisors now owns 21,302 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 1,109 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in shares of Advaxis by 115.0% in the second quarter. PNC Financial Services Group Inc. now owns 21,500 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 11,500 shares during the last quarter. 58.37% of the stock is currently owned by institutional investors and hedge funds.
Advaxis Company Profile
Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.
Receive News & Stock Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related stocks with our FREE daily email newsletter.